J S Kovach, A J Schutt, R G Hahn, R J Reitemeier, C G Moertel. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Adenocarcinoma/drug therapyAdultAgedAlopecia/chemically inducedAntineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useCentral Nervous System/drug effectsColonic Neoplasms/drug therapyCyclic P-Oxides/administration & dosageCyclic P-Oxides/adverse effectsCyclic P-Oxides/therapeutic useCyclophosphamide/therapeutic useDigestive System/drug effectsDrug EvaluationEthylamines/administration & dosageEthylamines/adverse effectsEthylamines/therapeutic useFemaleHumansImmunosuppressive Agents/administration & dosageImmunosuppressive Agents/adverse effectsImmunosuppressive Agents/therapeutic useInjections, IntravenousLeukopenia/chemically inducedMaleMiddle AgedNeurologic ManifestationsOxazines/administration & dosageOxazines/adverse effectsOxazines/therapeutic useRectal Neoplasms/drug therapyThrombocytopenia/chemically inducedUrinary Bladder/drug effects
Substances: See more » Antineoplastic AgentsCyclic P-OxidesEthylaminesImmunosuppressive AgentsOxazinesCyclophosphamide
Year: 1974 PMID: 4837137 DOI: 10.1159/000224886
Source DB: PubMed Journal: Oncology ISSN: 0030-2414 Impact factor: 2.935